Global Market Access Director will lead US pricing, reimbursement, and payer access strategy for the launch the oral liquid suspension of Miglustat, in Gaucher Disease, Niemann-Pick Disease - Type C, Fabry’s Disease and Batten Disease, while also shaping and influencing the global pricing and reimbursement (P&R) strategy for Miglustat worldwide.
Based in the US office in Bedminster, NJ, this highly strategic role requires deep expertise in the US payer landscape, strong negotiation capabilities, and the ability to translate US market insights into globally relevant access strategies for a rare pediatric disease with high unmet need.
RESPONSIBILITIES
- Define and execute the US pricing and reimbursement strategy for TX‑01, ensuring optimal coverage and access across US payers.
PROFILE
- Senior, strategic market access leader with proven experience in US payer engagement and negotiations.